肺纖維化合并肺氣腫的研究進展_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

許飛 ¹ , 陳群慧 ² ,  李鋒 ¹

1. ;
2. ;

Corresponding?author：

李鋒, Email: lifeng741@aliyun.com

Keywords：

DOI：

10.7507/1671-6205.201903075

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 許飛, 陳群慧, 李鋒. 肺纖維化合并肺氣腫的研究進展. Chinese Journal of Respiratory and Critical Care Medicine, 2019, 18(6): 587-590. doi: 10.7507/1671-6205.201903075 Copy

1.	Cottin V, Nunes H, Brillet PY, et al. Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J, 2005, 26(4): 586-593.
2.	Jankowich MD, Rounds SIS. Combined pulmonary fibrosis and emphysema syndrome: a review. Chest, 2012, 141(1): 222-231.
3.	Papaioannou AI, Kostikas K, Manali ED, et al. Combined pulmonary fibrosis and emphysema: the many aspects of a cohabitation contract. Respir Med, 2016, 117: 14-26.
4.	Papiris SA, Triantafillidou C, Manali ED, et al. Combined pulmonary fibrosis and emphysema. Expert Rev Respir Med, 2013, 7(1): 19-31; quiz 32.
5.	Fujimoto K, Kitaguchi Y, Kubo K, et al. Clinical analysis of chronic obstructive pulmonary disease phenotypes classified using high-resolution computed tomography. Respirology, 2006, 11(6): 731-740.
6.	Washko GR, Hunninghake GM, Fernandez IE, et al. Lung volumes and emphysema in smokers with interstitial lung abnormalities. N Engl J Med, 2011, 364(10): 897-906.
7.	Ryerson CJ, Hartman T, Elicker BM, et al. Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis. Chest, 2013, 144(1): 234-240.
8.	Mejía M, Carrillo G, Rojas-Serrano J, et al. Idiopathic pulmonary fibrosis and emphysema: decreased survival associated with severe pulmonary arterial hypertension. Chest, 2009, 136(1): 10-15.
9.	Yoon HY, Kim TH, Seo JB, et al. Effects of emphysema on physiological and prognostic characteristics of lung function in idiopathic pulmonary fibrosis. Respirology, 2019, 24(1): 55-62.
10.	Chae KJ, Jin GY, Han YM, et al. Prevalence and progression of combined pulmonary fibrosis and emphysema in asymptomatic smokers: a case-control study. Eur Radiol, 2015, 25(8): 2326-2334.
11.	Kumar A, Cherian SV, Vassallo R, et al. Current concepts in pathogenesis, diagnosis, and management of smoking-related interstitial lung diseases. Chest, 2018, 154(2): 394-408.
12.	Lin H, Jiang S. Combined pulmonary fibrosis and emphysema (CPFE): an entity different from emphysema or pulmonary fibrosis alone. J Thorac Dis, 2015, 7(4): 767-779.
13.	Saito A, Horie M, Nagase T. TGF-β signaling in lung health and disease. Int J Mol Sci, 2018, 19(8): E2460.
14.	Barratt SL, Flower VA, Pauling JD, et al. VEGF (vascular endothelial growth factor) and fibrotic lung disease. Int J Mol Sci, 2018, 19(5): E1269.
15.	Xu L, Yan DR, Zhu SL, et al. KL-6 regulated the expression of HGF, collagen and myofibroblast differentiation. Eur Rev Med Pharmacol Sci, 2013, 17(22): 3073-3077.
16.	Xu L, Bian W, Gu XH, et al. Differing expression of cytokines and tumor markers in combined pulmonary fibrosis and emphysema compared to emphysema and pulmonary fibrosis. COPD, 2017, 14(2): 245-250.
17.	Stanley SE, Merck SJ, Armanios M. Telomerase and the genetics of emphysema susceptibility. implications for pathogenesis paradigms and patient care. Ann Am Thorac Soc, 2016, 13(Suppl 5): S447-S451.
18.	Molina-Molina M, Borie R. Clinical implications of telomere dysfunction in lung fibrosis. Curr Opin Pulm Med, 2018, 24(5): 440-444.
19.	Hoffman TW, van Moorsel CHM, Borie R, et al. Pulmonary phenotypes associated with genetic variation in telomere-related genes. Curr Opin Pulm Med, 2018, 24(3): 269-280.
20.	Cottin V, Reix P, Khouatra C, et al. Combined pulmonary fibrosis and emphysema syndrome associated with familial SFTPC mutation. Thorax, 2011, 66(10): 918-919.
21.	Epaud R, Delestrain C, Louha M, et al. Combined pulmonary fibrosis and emphysema syndrome associated with ABCA3 mutations. Eur Respir J, 2014, 43(2): 638-641.
22.	Hanaoka M, Ito M, Droma Y, et al. Comparison of gene expression profiling between lung fibrotic and emphysematous tissues sampled from patients with combined pulmonary fibrosis and emphysema. Fibrogenesis Tissue Repair, 2012, 5(1): 17.
23.	Ciccarese F, Attina D, Zompatori M. Combined pulmonary fibrosis and emphysema (CPFE): what radiologist should know. Radiol Med, 2016, 121(7): 564-572.
24.	Feldhaus FW, Theilig DC, Hubner RH, et al. Quantitative CT analysis in patients with pulmonary emphysema: is lung function influenced by concomitant unspecific pulmonary fibrosis?. Int J Chron Obstruct Pulmon Dis, 2019, 14: 1583-1593.
25.	Ciftci F, Gülp?nar B, Atasoy C, et al. Combined pulmonary fibrosis and emphysema: How does cohabitation affect respiratory functions?. Adv Med Sci, 2019, 64(2): 285-291.
26.	King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med, 2014, 370(22): 2083-2092.
27.	Charleston-Villalobos S, Castaneda-Villa N, Gonzalez-Camarena R, et al. Acoustic evaluation of pirfenidone on patients with combined pulmonary fibrosis emphysema syndrome. Conf Proc IEEE Eng Med Biol Soc, 2016, 2016: 3175-3178.
28.	Oltmanns U, Kahn N, Palmowski K, et al. Pirfenidone in idiopathic pulmonary fibrosis: real-life experience from a German tertiary referral center for interstitial lung diseases. Respiration, 2014, 88(3): 199-207.
29.	Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med, 2014, 370(22): 2071-2082.
30.	Cottin V, Le Pavec J, Prévot G, et al. Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome. Eur Respir J, 2010, 35(1): 105-111.
31.	Sugino K, Ishida F, Kikuchi N, et al. Comparison of clinical characteristics and prognostic factors of combined pulmonary fibrosis and emphysema versus idiopathic pulmonary fibrosis alone. Respirology, 2014, 19(2): 239-245.
32.	Jacob J, Bartholmai BJ, Rajagopalan S, et al. Likelihood of pulmonary hypertension in patients with idiopathic pulmonary fibrosis and emphysema. Respirology, 2018, 23(6): 593-599.
33.	Tanabe N, Taniguchi H, Tsujino I, et al. Multi‐institutional retrospective cohort study of patients with severe pulmonary hypertension associated with respiratory diseases. Respirology, 2015, 20(5): 805-812.
34.	Gao L, Xie S, Liu H, et al. Lung cancer in patients with combined pulmonary fibrosis and emphysema revisited with the 2015 World Health Organization classification of lung tumors. Clin Respir J, 2018, 12(2): 652-658.
35.	Koo HJ, Do KH, Lee JB, et al. Lung cancer in combined pulmonary fibrosis and emphysema: a systematic review and meta-analysis. PLoS One, 2016, 11(9): e0161437.
36.	Li C, Wu W, Chen N, et al. Clinical characteristics and outcomes of lung cancer patients with combined pulmonary fibrosis and emphysema: a systematic review and meta-analysis of 13 studies. J Thorac Dis, 2017, 9(12): 5322-5334.
37.	Wells AU, Desai SR, Rubens MB, et al. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med, 2003, 167(7): 962-969.
38.	Zhang L, Zhang C, Dong F, et al. Combined pulmonary fibrosis and emphysema: a retrospective analysis of clinical characteristics, treatment and prognosis. BMC Pulm Med, 2016, 16(1): 137.

1. Cottin V, Nunes H, Brillet PY, et al. Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J, 2005, 26(4): 586-593.
2. Jankowich MD, Rounds SIS. Combined pulmonary fibrosis and emphysema syndrome: a review. Chest, 2012, 141(1): 222-231.
3. Papaioannou AI, Kostikas K, Manali ED, et al. Combined pulmonary fibrosis and emphysema: the many aspects of a cohabitation contract. Respir Med, 2016, 117: 14-26.
4. Papiris SA, Triantafillidou C, Manali ED, et al. Combined pulmonary fibrosis and emphysema. Expert Rev Respir Med, 2013, 7(1): 19-31; quiz 32.
5. Fujimoto K, Kitaguchi Y, Kubo K, et al. Clinical analysis of chronic obstructive pulmonary disease phenotypes classified using high-resolution computed tomography. Respirology, 2006, 11(6): 731-740.
6. Washko GR, Hunninghake GM, Fernandez IE, et al. Lung volumes and emphysema in smokers with interstitial lung abnormalities. N Engl J Med, 2011, 364(10): 897-906.
7. Ryerson CJ, Hartman T, Elicker BM, et al. Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis. Chest, 2013, 144(1): 234-240.
8. Mejía M, Carrillo G, Rojas-Serrano J, et al. Idiopathic pulmonary fibrosis and emphysema: decreased survival associated with severe pulmonary arterial hypertension. Chest, 2009, 136(1): 10-15.
9. Yoon HY, Kim TH, Seo JB, et al. Effects of emphysema on physiological and prognostic characteristics of lung function in idiopathic pulmonary fibrosis. Respirology, 2019, 24(1): 55-62.
10. Chae KJ, Jin GY, Han YM, et al. Prevalence and progression of combined pulmonary fibrosis and emphysema in asymptomatic smokers: a case-control study. Eur Radiol, 2015, 25(8): 2326-2334.
11. Kumar A, Cherian SV, Vassallo R, et al. Current concepts in pathogenesis, diagnosis, and management of smoking-related interstitial lung diseases. Chest, 2018, 154(2): 394-408.
12. Lin H, Jiang S. Combined pulmonary fibrosis and emphysema (CPFE): an entity different from emphysema or pulmonary fibrosis alone. J Thorac Dis, 2015, 7(4): 767-779.
13. Saito A, Horie M, Nagase T. TGF-β signaling in lung health and disease. Int J Mol Sci, 2018, 19(8): E2460.
14. Barratt SL, Flower VA, Pauling JD, et al. VEGF (vascular endothelial growth factor) and fibrotic lung disease. Int J Mol Sci, 2018, 19(5): E1269.
15. Xu L, Yan DR, Zhu SL, et al. KL-6 regulated the expression of HGF, collagen and myofibroblast differentiation. Eur Rev Med Pharmacol Sci, 2013, 17(22): 3073-3077.
16. Xu L, Bian W, Gu XH, et al. Differing expression of cytokines and tumor markers in combined pulmonary fibrosis and emphysema compared to emphysema and pulmonary fibrosis. COPD, 2017, 14(2): 245-250.
17. Stanley SE, Merck SJ, Armanios M. Telomerase and the genetics of emphysema susceptibility. implications for pathogenesis paradigms and patient care. Ann Am Thorac Soc, 2016, 13(Suppl 5): S447-S451.
18. Molina-Molina M, Borie R. Clinical implications of telomere dysfunction in lung fibrosis. Curr Opin Pulm Med, 2018, 24(5): 440-444.
19. Hoffman TW, van Moorsel CHM, Borie R, et al. Pulmonary phenotypes associated with genetic variation in telomere-related genes. Curr Opin Pulm Med, 2018, 24(3): 269-280.
20. Cottin V, Reix P, Khouatra C, et al. Combined pulmonary fibrosis and emphysema syndrome associated with familial SFTPC mutation. Thorax, 2011, 66(10): 918-919.
21. Epaud R, Delestrain C, Louha M, et al. Combined pulmonary fibrosis and emphysema syndrome associated with ABCA3 mutations. Eur Respir J, 2014, 43(2): 638-641.
22. Hanaoka M, Ito M, Droma Y, et al. Comparison of gene expression profiling between lung fibrotic and emphysematous tissues sampled from patients with combined pulmonary fibrosis and emphysema. Fibrogenesis Tissue Repair, 2012, 5(1): 17.
23. Ciccarese F, Attina D, Zompatori M. Combined pulmonary fibrosis and emphysema (CPFE): what radiologist should know. Radiol Med, 2016, 121(7): 564-572.
24. Feldhaus FW, Theilig DC, Hubner RH, et al. Quantitative CT analysis in patients with pulmonary emphysema: is lung function influenced by concomitant unspecific pulmonary fibrosis?. Int J Chron Obstruct Pulmon Dis, 2019, 14: 1583-1593.
25. Ciftci F, Gülp?nar B, Atasoy C, et al. Combined pulmonary fibrosis and emphysema: How does cohabitation affect respiratory functions?. Adv Med Sci, 2019, 64(2): 285-291.
26. King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med, 2014, 370(22): 2083-2092.
27. Charleston-Villalobos S, Castaneda-Villa N, Gonzalez-Camarena R, et al. Acoustic evaluation of pirfenidone on patients with combined pulmonary fibrosis emphysema syndrome. Conf Proc IEEE Eng Med Biol Soc, 2016, 2016: 3175-3178.
28. Oltmanns U, Kahn N, Palmowski K, et al. Pirfenidone in idiopathic pulmonary fibrosis: real-life experience from a German tertiary referral center for interstitial lung diseases. Respiration, 2014, 88(3): 199-207.
29. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med, 2014, 370(22): 2071-2082.
30. Cottin V, Le Pavec J, Prévot G, et al. Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome. Eur Respir J, 2010, 35(1): 105-111.
31. Sugino K, Ishida F, Kikuchi N, et al. Comparison of clinical characteristics and prognostic factors of combined pulmonary fibrosis and emphysema versus idiopathic pulmonary fibrosis alone. Respirology, 2014, 19(2): 239-245.
32. Jacob J, Bartholmai BJ, Rajagopalan S, et al. Likelihood of pulmonary hypertension in patients with idiopathic pulmonary fibrosis and emphysema. Respirology, 2018, 23(6): 593-599.
33. Tanabe N, Taniguchi H, Tsujino I, et al. Multi‐institutional retrospective cohort study of patients with severe pulmonary hypertension associated with respiratory diseases. Respirology, 2015, 20(5): 805-812.
34. Gao L, Xie S, Liu H, et al. Lung cancer in patients with combined pulmonary fibrosis and emphysema revisited with the 2015 World Health Organization classification of lung tumors. Clin Respir J, 2018, 12(2): 652-658.
35. Koo HJ, Do KH, Lee JB, et al. Lung cancer in combined pulmonary fibrosis and emphysema: a systematic review and meta-analysis. PLoS One, 2016, 11(9): e0161437.
36. Li C, Wu W, Chen N, et al. Clinical characteristics and outcomes of lung cancer patients with combined pulmonary fibrosis and emphysema: a systematic review and meta-analysis of 13 studies. J Thorac Dis, 2017, 9(12): 5322-5334.
37. Wells AU, Desai SR, Rubens MB, et al. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med, 2003, 167(7): 962-969.
38. Zhang L, Zhang C, Dong F, et al. Combined pulmonary fibrosis and emphysema: a retrospective analysis of clinical characteristics, treatment and prognosis. BMC Pulm Med, 2016, 16(1): 137.

Previous Article
肺隔離癥合并軍團菌感染及血清 CA19-9 升高一例
Next Article
急性呼吸窘迫綜合征機械通氣患者呼氣末正壓設定的方法

Chinese Journal of Respiratory and Critical Care Medicine

肺纖維化合并肺氣腫的研究進展

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content